Immunovant Inc. (IMVT)

Business: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

IPO Date: 21-Jun-2019

Exec. Chairperson of the Board: Dr. Frank M. Torti M.B.A., M.D., MBA

CEO & Director: Dr. Peter Salzmann M.B.A., M.D.

Listing: NASDAQ: IMVT

Country: United States

Headquarters: New York, NY

Website: https://immunovant.com

Market cap: $473.01 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-156.73 Mln

Cash: $493.82 Mln

Total Debt: $2.36 Mln

Insider's Holding: 64.61%

Liquidity: Low

52 Week range: $3.15 - 11.37

Shares outstanding: 116,505,000

5 Years Aggregate:

• CFO: $-399.64 Mln
• EBITDA: $-330.06 Mln
• Net Profit: $-467.29 Mln